



Camber Pharmaceuticals, Inc.
 800 Centennial Avenue, Suite 1
 Piscataway, NJ 08854
 Tel: 732-529-0430

Office of the Attorney General
 State of Vermont

To Whom It May Concern,

Pursuant to 18 V.S.A. §4637 (b) and (c), Camber Pharmaceuticals, Inc. is hereby providing notification and subsequent supplemental information regarding the introduction of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

NDC	Description	Market Launch Date	Wholesale Acquisition Cost
31722002932	Deferasirox Oral Granules 90mg 30ct	6/12/2023	\$1,000.00
31722003032	Deferasirox Oral Granules 180mg 30ct	6/12/2023	\$2,000.00
31722003132	Deferasirox Oral Granules 360mg 30ct	6/12/2023	\$4,000.00

Additional Information Required	Camber's Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	At market launch, Camber communicates with customers through press releases, internet marketing via our website, and through private conversations with corporate buyers. These products are sold in the United States only. Camber Pharmaceuticals, Inc. considers various factors in deciding the price at which to set its prescription drugs, including, but not limited to: the current competitive landscape and pricing environment; manufacturing considerations; supply considerations; profitability; costs, including research and development costs; contracts and relationships with customers; public policy considerations; and legal considerations.
The estimated volume of patients who may be prescribed the drug	Deferasirox: 16,000,000 Camber Pharmaceuticals, Inc. does not evaluate the number of patients that may be prescribed these products. The estimation is based on the therapeutic category and the number of cases in the United States of the disease state that the medication is indicated for.



Camber Pharmaceuticals, Inc.
800 Centennial Avenue, Suite 1
Piscataway, NJ 08854
Tel: 732-529-0430

Additional Information Required	Camber's Submission
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	This product was not granted breakthrough therapy designation nor priority review.
The date and price of acquisition if the drug was not developed by the manufacturer	N/A. This product was not acquired.

If any additional information is needed, please let me know.

Christopher Bormida
Commercial Strategy and Operations Analyst
cbormida@camberpharma.com